A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy

Trial Profile

A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 08 Mar 2018 The study has been suspended in Poland.
    • 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 21 Feb 2018 Planned End Date changed from 30 Aug 2019 to 15 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top